What is Eutropics?
Eutropics Pharmaceuticals is at the forefront of precision medicine, specializing in the development of the PRIMABS-Dx platform. This proprietary technology generates functional predictive biomarkers designed to enhance treatment decisions for cancer patients, particularly in hematologic malignancies. The platform's strength lies in its scalable, multiplexed companion diagnostics, which leverage mitochondrial priming biology to overcome the limitations of existing predictive biomarkers. By providing oncologists and healthcare providers with more accurate diagnostic solutions, Eutropics aims to improve patient outcomes and reduce the economic burden associated with ineffective cancer therapies.
How much funding has Eutropics raised?
Eutropics has raised a total of $102K across 1 funding round:
Debt
$102K
Debt (2021): $102K with participation from PPP
What's next for Eutropics?
With substantial late-stage capital infusion, Eutropics Pharmaceuticals is poised for significant expansion and market penetration. The recent strategic investment signals strong confidence from stakeholders in the company's technology and its potential to revolutionize oncology diagnostics. Future endeavors will likely focus on scaling production of the PRIMABS-Dx platform, expanding its clinical validation across a broader range of cancers, and forging strategic partnerships within the healthcare ecosystem. This funding will be critical in accelerating Eutropics' mission to deliver actionable insights for personalized cancer treatment.
See full Eutropics company page
